Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$11.04
-3.1%
$11.03
$8.98
▼
$22.55
$196.83M1.13188,630 shs208,691 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.04
+0.1%
$11.61
$9.46
▼
$23.29
$998.30M1.141.67 million shs1.72 million shs
ODTX
Odyssey Therapeutics
$16.94
-7.6%
$19.93
$15.10
▼
$29.05
$930.59MN/A324,952 shs677,842 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.54
-5.2%
$11.06
$9.11
▼
$21.34
$891.10M-0.0517,084 shs10,505 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-3.07%+7.18%-1.25%+0.09%-34.52%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+0.09%-11.68%+3.66%-29.95%-18.46%
ODTX
Odyssey Therapeutics
-7.63%-11.49%-10.84%-35.81%+1,693,999,900.00%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-6.79%-8.41%+20.40%-2.62%-28.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$11.04
-3.1%
$11.03
$8.98
▼
$22.55
$196.83M1.13188,630 shs208,691 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.04
+0.1%
$11.61
$9.46
▼
$23.29
$998.30M1.141.67 million shs1.72 million shs
ODTX
Odyssey Therapeutics
$16.94
-7.6%
$19.93
$15.10
▼
$29.05
$930.59MN/A324,952 shs677,842 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$11.54
-5.2%
$11.06
$9.11
▼
$21.34
$891.10M-0.0517,084 shs10,505 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-3.07%+7.18%-1.25%+0.09%-34.52%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+0.09%-11.68%+3.66%-29.95%-18.46%
ODTX
Odyssey Therapeutics
-7.63%-11.49%-10.84%-35.81%+1,693,999,900.00%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-6.79%-8.41%+20.40%-2.62%-28.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.57
Moderate Buy$20.0081.16% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.60
Moderate Buy$31.33183.82% Upside
ODTX
Odyssey Therapeutics
2.80
Moderate Buy$34.67104.64% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.60
Moderate Buy$39.67243.73% Upside

Current Analyst Ratings Breakdown

Latest KROS, MLTX, ODTX, and PHAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/12/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Set Price TargetOutperform$34.00
11/11/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
UpgradeSell (D+) ➝ Hold (C-)
11/10/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Reiterated RatingSell (D-)
11/9/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
UpgradeHold ➝ Strong-Buy
11/6/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Initiated CoverageBuy$57.00
11/6/2026
ODTX
Odyssey Therapeutics
Initiated CoverageBuy$40.00
10/29/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Boost Price TargetBuy$38.00 ➝ $41.00
10/28/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
Reiterated RatingOutperform
10/27/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
UpgradeSell (D) ➝ Sell (D+)
10/23/2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
UpgradeStrong Sell ➝ Hold
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$244.06M0.89$5.00 per share2.21$14.22 per share0.78
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.48 per shareN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/A$7.82 per shareN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$376.13M2.17$0.18 per share62.78$4.11 per share2.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$87.01M-$2.82N/AN/AN/A-256.60%-21.85%-19.83%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.67N/AN/AN/AN/A-79.95%-56.40%N/A
ODTX
Odyssey Therapeutics
N/A-$9.13N/AN/AN/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$2.85M$0.3236.0622.63N/A6.23%8.70%4.93%N/A

Latest KROS, MLTX, ODTX, and PHAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$0.96$0.70+$1.66$0.70$14.76 million$40.01 million
11/4/2026Q3 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.8326-$0.93-$0.0974-$0.93N/AN/A
10/27/2026Q3 2026
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$0.21$0.30+$0.09$0.30$117.60 million$117.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
18.14
18.14
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.26
9.13
9.13
ODTX
Odyssey Therapeutics
N/A
12.94
12.94
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.32
3.23
2.65

Institutional Ownership

CompanyInstitutional Ownership
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
ODTX
Odyssey Therapeutics
N/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
9219.62 million17.15 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable
ODTX
Odyssey Therapeutics
10048.07 millionN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
40770.78 million69.31 millionNot Optionable

Recent News About These Companies

HC Wainwright Weighs in on Pharming Group Q4 Earnings
Can Pharming (NASDAQ:PHAR) Extend Growth Before CVID Data?
Pharming Group Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$11.04 -0.35 (-3.07%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$11.07 +0.03 (+0.27%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.04 +0.01 (+0.09%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$11.10 +0.07 (+0.59%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Odyssey Therapeutics NASDAQ:ODTX

$16.94 -1.40 (-7.63%)
As of 11/20/2026 03:59 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$11.54 -0.63 (-5.18%)
Closing price 11/20/2026 03:46 PM Eastern
Extended Trading
$11.51 -0.03 (-0.29%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.